Ultragenyx Pharma (RARE) PT Lowered to $45 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections, more earnings
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Price: $16.17 +0.43%
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 21 | New: 16
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 21 | New: 16
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $45.00 (from $66.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Bright Minds Biosciences Inc. (DRUG) PT Lowered to $107 at Baird amid partial clinical hold
- Teladoc (TDOC) PT Raised to $11 at Piper Sandler
- Papa John's (PZZA) PT Lowered to $21 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
